UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Predictors of optimal virological response to potent antiretroviral therapy

AIDS (London), 1999-10, Vol.13 (14), p.1873-1880

1999

Volltextzugriff (PDF)

Polyglutamation of methotrexate: is methotrexate a prodrug?

The Journal of clinical investigation, 1985-09, Vol.76 (3), p.907-912

1985

Volltextzugriff (PDF)

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

British journal of cancer, 1999-02, Vol.79 (5-6), p.915-920

1999

Volltextzugriff (PDF)

The pharmacology and clinical use of methotrexate

The New England journal of medicine, 1983-11, Vol.309 (18), p.1094

1983

Volltextzugriff (PDF)

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

Investigational new drugs, 1997-01, Vol.15 (2), p.157-163

1997

Volltextzugriff (PDF)

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion

Clinical cancer research, 1996-10, Vol.2 (10), p.1685-1692

1996

Volltextzugriff (PDF)

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration

Journal of clinical oncology, 1991-03, Vol.9 (3), p.464-467

1991

Volltextzugriff (PDF)

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

Cancer chemotherapy and pharmacology, 2000, Vol.45 (5), p.423-427

2000

Volltextzugriff (PDF)

Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma

American journal of clinical oncology, 1995-12, Vol.18 (6), p.488-490

1995

Volltextzugriff (PDF)

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach

Annals of oncology, 1992-01, Vol.3 (1), p.79-81

1992

Volltextzugriff (PDF)

Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule

Cancer research (Chicago, Ill.), 1992-02, Vol.52 (3), p.521-524

1992

Volltextzugriff (PDF)

Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate

The Journal of clinical investigation, 1985-10, Vol.76 (4), p.1323-1329

1985

Volltextzugriff (PDF)

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

Investigational new drugs, 1994-01, Vol.12 (2), p.137-141

1994

Volltextzugriff (PDF)

Phase I Trial of Piritrexim Capsules Using Prolonged, Low-Dose Oral Administration for the Treatment of Advanced Malignancies

JNCI : Journal of the National Cancer Institute, 1991-01, Vol.83 (1), p.51-55

1991

Volltextzugriff (PDF)

Oral piritrexim : a phase II study in patients with advanced soft tissue sarcoma

Investigational new drugs, 1992-07, Vol.10 (2), p.97-98

1992

Volltextzugriff (PDF)

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

Cancer, 1992-02, Vol.69 (4), p.1008-1011

1992

Volltextzugriff (PDF)

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion

Cancer chemotherapy and pharmacology, 1993-01, Vol.31 (4), p.283-288

1993

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3007-3007

2011

Volltextzugriff (PDF)

Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 1998, Vol.41 (2), p.167

1998

Volltextzugriff (PDF)

Drug resistance in cancer

Cancer treatment reports, 1984-01, Vol.68 (1), p.87

1984

Volltextzugriff (PDF)

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer

Cancer, 1991-05, Vol.67 (9), p.2253-2257

1991

Volltextzugriff (PDF)

Potential Pitfalls in the Evaluation of the Usefulness of Hemodialysis for the Removal of Lithium

Clinical toxicology (Philadelphia, Pa.), 1982-01, Vol.19 (4), p.341-352

1982

Volltextzugriff (PDF)

Initial clinical trial and pharmacokinetics of ThymitaTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 1998, Vol.41 (2), p.167-170

1998

Volltextzugriff (PDF)

Symposium on cellular resistance to anticancer drugs. Introduction

Cancer treatment reports, 1983-10, Vol.67 (10), p.855

1983

Volltextzugriff (PDF)

Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule

Cancer research (Chicago, Ill.), 1990-08, Vol.50 (15), p.4464

1990

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Humans
(38)
Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Biological And Medical Sciences
(32)
Medical Sciences
(32)
Pharmacology. Drug Treatments
(32)
Antineoplastic Agents
(28)
Female
(27)
Adult
(26)
Male
(26)
Oncology
(24)
Chemotherapy
(23)
Middle Aged
(23)
Aged
(22)
Neoplasms - Drug Therapy
(18)
Drug Administration Schedule
(13)
Administration, Oral
(11)
Drug Evaluation
(10)
Pyrimidines - Administration & Dosage
(10)
Pyrimidines - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictors of optimal virological response to potent antiretroviral therapy

Polyglutamation of methotrexate: is methotrexate a prodrug?

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

The pharmacology and clinical use of methotrexate

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach

Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule

Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

Phase I Trial of Piritrexim Capsules Using Prolonged, Low-Dose Oral Administration for the Treatment of Advanced Malignancies

Oral piritrexim : a phase II study in patients with advanced soft tissue sarcoma

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer

Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors

Drug resistance in cancer

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer

Potential Pitfalls in the Evaluation of the Usefulness of Hemodialysis for the Removal of Lithium

Initial clinical trial and pharmacokinetics of ThymitaTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

Symposium on cellular resistance to anticancer drugs. Introduction

Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule

Suchergebnisse filtern